- About us
- A new Institute dedicated to combating leukemia
- Medical-scientific program
- History of Hematology on the Saint-Louis Campus
- The Leukemia Institute’s governance
- Press
- Contact us
- Our news
- Profile of Valéria Bisio, Research Officer
- Creation of a Hemato-Oncogenetics Unit
- Profile of Alice Gros, a peer-support patient
- Winners of the Leukemia Institute’s first call for projects
- Profile of Julien Calvo, researcher
- Support us
- Join us
- You are
- Patients and relatives
- To be cared for and supported
- Become an expert patient
- Discover the Leukemia Institute
- Researchers
- Research
- Clinical trials
- Discover the Leukemia Institute
- Healthcare professionals
- Refer a patient
- Our clinical research
- Discover the Leukemia Institute
- Industry partners
- Discover the Leukemia Institute
- Translational research
- Donors
- Support us
- Discover the Leukemia Institute
- Care
- Patient care
- Being Treated at the Leukemia Institute
- Cancer treatments
- Supportive Care
- Open Multidisciplinary Meetings
- Our clinical services
- Saint-Louis Hospital – Department of adult hematology
- Saint-Louis Hospital – Hematology Transplant Unit
- Saint-Louis Hospital – Department of Pharmacology and Clinical Investigations
- Saint-Louis Hospital – Adolescent and Young Adult Unit
- Saint-Louis Hospital – Outpatient Hemato-oncogenetics Unit
- Saint-Louis Hospital – Department of senior hematology
- Robert-Debré Hospital – Department of pediatric hematology and immunology
- Necker Hospital – Department of Adult Hematology
- Cochin–Port Royal Hospital – Department of clinical hematology
- Avicenne Hospital – Department of clinical hematology and cell therapy
- Our medical laboratories
- Hematology Medical Laboratory, Michaela Fontenay
- Hematology Medical Laboratory, Jean Soulier
- Molecular Genetics Unit, Hélène Cavé
- Hematology Medical Laboratory, Vahid Asnafi
- Patient information
- Acute Myeloid Leukemias
- Acute Lymphoblastic Leukemias
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
- Cancer treatments
- Supportive Care
- Psychological Support
- Research
- Our research teams
- Hugues de Thé’s team – Molecular pathology
- Raphaël Itzykson’s team – Functional precision medicine for leukemia
- Michaela Fontenay’s team – Normal and pathological hematopoiesis
- Françoise Pflumio’s team – Niche, Cancer, and Radiation in Hematopoiesis
- Sylvie Méléard’s team – Population Evolution and Interaction Particle Systems
- David Michonneau’s team – Translational Immunology in Immunotherapy and Hematology (TIGITH)
- Lina Benajiba’s team – Identification and targeting of extrinsic regulators of myeloid malignancies
- Karl Balabanian’s team – Lymphoid niches, Chemokines and Immuno-hematological syndromes
- Alexandre Puissant’s team – Molecular Mechanisms of Acute Myeloid Leukemia Development
- Stéphane Giraudier’s team – Chronic Myeloid Malignancies, Microenvironment & Translational Research
- Diana Passaro’s team – Leukemia & Niche Dynamics
- Camille Lobry’s team – Genetic and Epigenetic control of Normal and Malignant Hematopoiesis
- Jean Soulier’s team – Stem cell dysfunction and secondary AML
- Sylvie Chevret’s team – Biostatistics and clinical epidemiology
- Our technological platforms
- Our clinical research
Accueil Care for patients with leukemia and related disorders Our clinical researchOur clinical research
...Our clinical research
The purpose of this page is to inform you about the clinical research conducted at the Leukemia Institute, to describe how health data and biological samples are used, and to remind participants of their rights regarding the use of their personal health data for research purposes.
Below, we also provide information about clinical research conducted by the Leukemia Institute in collaboration with AP-HP Saint-Louis Hospital, Robert Debré Hospital, Necker Hospital, Cochin Hospital, Inserm, and other partners.
eTHEMA Registry
The eTHEMA registry, supported by the French National Research Agency as part of the government’s Future Investment Plan, collects research data on leukemia and related diseases to continually help physicians, biologists, and research technicians at three AP-HP hospitals (Saint-Louis, Robert Debré, and Avicenne) understand and manage these diseases.
The data recorded in the eTHEMA CRF reflect the source data collected prospectively in hospital records or lab results. At the same time, data from routine biological samples (blood, bone marrow) or research samples collected and frozen at the certified SLS/THEMA Biological Resource Center will be located in the MEARY translational research building near the eTHEMA data center, under the responsibility of Professor Emmanuelle Clappier (Biological Hematology Laboratory, Saint-Louis Hospital, Paris).
Our biological collections
The Leukemia Institute contributes in the Biobank Observatory for Translational Research in Hematology (BiRTH) and the RIME Observatory (National Observatory for Bone Marrow Failure), which aim to collect standardized (clinical and biological data) and anonymous information for each patient on a prospective and retrospective basis.
Reuse of biological samples and associated data for scientific research purposes
Biological samples collected during care or clinical leukemia research may be stored in a biological collection, along with certain health data, for the purposes of scientific studies, reviews, and research.
During a consultation or hospital stay, biological samples may be taken for biological, genetic, or other analyses for diagnostic, monitoring, or treatment purposes. These samples may include various types of specimens (blood, urine, saliva, skin, stool, tissue, etc.).
If some of the samples collected have not been used for the analyses initially planned, patients and, if necessary, their parents, may be asked to give their consent for the remaining samples to be stored in a biological collection. This enables research through scientific or clinical programs focusing on genetic diseases and, more broadly, rare diseases. Related clinical data (such as sociodemographic information, the diagnosis, symptoms, treatments administered, and test results) will also be stored with these samples for the purpose of conducting this research.In this context, patients will have signed a consent form or received an information document specifying:
- The type of samples stored, the objectives of the scientific research, the storage conditions, and the related treatment data.
- The regulations applicable to the processing of personal data, in particular the process to code samples and data to guarantee the anonymity of the individuals concerned.
- Patients’ rights to access, correct, and delete their data, restrict or object to its processing, and regarding the portability of their data, in accordance with the General Data Protection Regulation (GDPR) and the French Data Protection Act, as well as the contact details of the persons to contact to exercise these rights.
Stay up to date by subscribing to the institute's newsletter
- Discover the Leukemia Institute
- Translational research
- Our clinical research
- Clinical trials
- Become an expert patient
- To be cared for and supported
- A new Institute dedicated to combating leukemia
Transparency portal, reuse of health data, and individual rights
For the purpose of clinical research conducted by or supported by the Leukemia Institute, each patient involved has signed a consent form or received an information letter. This document specifies that the health data collected during the study may be reused for other scientific research to improve medical and therapeutic knowledge about the disease being studied.
For each clinical study, participant information is compiled in a database after being pseudonymized. This data does not directly identify individuals, as it does not include first or last names or contact information. Only the research team has the list that links the assigned code to the person’s identity.